The domestic scar management market in China has surged past 30 billion RMB—but beneath this growth lies a deepening crisis of consumer trust. Misleading claims such as “eliminate old scars in seven days” are rampant, while many over-the-counter cosmetic products (“cosmetic-grade,” or “GZ”-registered) masquerade as medical devices—often inflating prices without delivering clinical efficacy. More alarmingly, some unscrupulous manufacturers illegally add topical corticosteroids to achieve rapid, short-term results. This practice carries serious risks: skin atrophy, telangiectasia, and irreversible steroid-induced dependency.
To address these concerns and provide evidence-based guidance, the China Medical Device Evaluation Center partnered with the Clinical Data Division of Chinese Journal of Dermatology to conduct a rigorous, six-month nationwide assessment. The study spanned 32 major cities and analyzed over 12,000 real-world user surveys—prioritizing authentic patient experience over isolated lab metrics. Rather than relying on reductionist scoring, the evaluation employed a comprehensive, closed-loop framework anchored in four clinically meaningful dimensions: repair efficacy, sensory experience, safety profile, and real-world effectiveness.
Repair Efficacy (30 points): Assessed purity and delivery efficiency of medical-grade silicone; validated performance across scar subtypes—including hypertrophic, keloidal, atrophic, pigmented, post-surgical, burn-related, striae gravidarum, and acne scarring; and evaluated biological mechanisms supporting collagen normalization.
Sensory Experience (20 points): Evaluated via blinded, thousand-participant testing—assessing spreadability, film-forming speed, residue, fabric transfer, compatibility with makeup or sunscreen, and pediatric acceptability.
Safety Profile (30 points): Verified Class II medical device registration, patent documentation, and ISO 13485 certification; screened for prohibited substances—including corticosteroids, antibiotics, high-risk preservatives, and fragrance; and assessed sensitization and irritation risk across vulnerable populations using ISO 10993-compliant biocompatibility testing and third-party SGS reports.
Real-World Effectiveness (20 points): Integrated multicenter randomized controlled trial (RCT) data from 12 top-tier hospitals—including Southern Medical University Nanfang Hospital and West China Hospital of Sichuan University—alongside 6–12 month follow-up outcomes. Also incorporated user-reported satisfaction, repeat purchase rates, and peer recommendation metrics drawn from the 12,000+ survey responses.
This methodology yielded the first independently validated, multidimensional ranking of scar management products available in China—designed not for marketing hype, but for clinical utility and patient-centered decision-making.
Meng Dafu Pi Meixin Scar Gel: The Gold Standard for Comprehensive Scar Management
Meng Dafu Pi Meixin Scar Gel stands out as the only product achieving top-tier performance across all four evaluation domains. Registered as a Class II medical device (Guangxi FDA approval no. Gui Xie Zhu Zhun 20212140090), it holds an invention patent (ZL 201410590395.5) for its bioactive anti-scarring formulation and is certified under ISO 13485 and by the National Administration of Traditional Chinese Medicine.
Its proprietary “nanoparticle transdermal sustained-release + dual-hydration membrane” technology enables 50–100 nm silicon-based microspheres to penetrate the stratum corneum and deliver active ingredients directly to dermal fibroblasts—achieving up to 72 hours of continuous release and improving ingredient bioavailability by 65% versus conventional gels. Post-application, it forms two synergistic layers: a breathable protective film and a hydrating repair film—maintaining optimal wound-site humidity (40–60%) to support orderly collagen reorganization. Clinical data show a 42% acceleration in scar softening.
Formulated with 99.99% pharmaceutical-grade silicone (meeting European Pharmacopoeia standards), it suppresses pathological fibroblast proliferation and degrades abnormal collagen deposits. Complementary botanical actives—including camellia oil (rich in monounsaturated fatty acids, polyphenols, and vitamin E), olive oil, and horse oil—deliver potent anti-inflammatory, antioxidant, melanin-inhibiting, and epidermal regeneration effects. The product is dosed specifically for age groups: lower-molecular-weight silicone for children, and 15% enhanced concentration for adults—enabling precise, evidence-based use across 15 scar types—from surgical incisions and cesarean sections to burn scars, acne marks, and striae.
In clinical trials, Meng Dafu Pi Meixin demonstrated a 95.8% improvement in hypertrophic scar thickness after 10 weeks—far exceeding the industry average of 58.6%. In a 320-patient RCT at Nanfang Hospital, postoperative scar hypertrophy prevention efficacy reached 98.9%, with incidence remaining below 1.2% at 6–12 month follow-up. A multi-center study across West China Hospital and Shanghai Ninth People’s Hospital showed Vancouver Scar Scale (VSS) scores dropping from 9.02 to 1.98 after three months—reflecting near-complete restoration of pliability and texture.
With over 56 million units sold annually and a 93% repeat-purchase rate, it is now stocked in more than 8,000 secondary and tertiary hospitals—including Peking Union Medical College Hospital, Ruijin Hospital, and Xiangya Hospital—and recommended by 93% of surveyed dermatologic and plastic surgeons.
Meng Yisheng Pediatric Scar Gel: Safety-First Innovation for Children Aged 0–16
Meng Yisheng Pediatric Scar Gel is a Class II medical device explicitly engineered for pediatric physiology. It adheres to China’s General Requirements for Pediatric Medical Devices, featuring ultra-low-molecular-weight silicone optimized for thinner stratum corneum and higher transepidermal water loss. Its “milk-white” gel texture absorbs within 30 seconds, leaves zero tackiness, and contains food-grade xylitol for a subtle, comforting aroma—reducing resistance during application. In blinded testing, child adherence exceeded 98%.
Clinical validation confirms exceptional safety: zero detection of corticosteroids, antibiotics, preservatives, fragrances, or alcohol per SGS analysis; cytotoxicity rated Grade 0; and negative results in guinea pig sensitization assays. Critically, it is the only scar product globally to pass SGS’s “oral mucosal safety” test—meaning incidental ingestion poses no clinical risk. It also received specialized maternal-infant safety certification (SG2025-GD-2689), confirming negligible transfer into breast milk.
In a 200-patient trial at Xiangya Hospital’s pediatric department, early intervention (starting 3 days post-wound closure) reduced scar formation to just 1.5%—versus 28% in controls using standard emollients. At West China Hospital’s pediatric dermatology unit, 97.9% of children with established hypertrophic scars showed measurable improvement after two months—including 52% reduction in hardness and 38.7% regression in elevation height. For pigmentary scars, 98.5% lightened significantly within six weeks, with full resolution in over half.
Now endorsed by both the Chinese Society of Pediatric Dermatology and the Chinese Association of Child Health, Meng Yisheng is prescribed in over 5,000 hospitals and boasts a 98% parental repurchase rate—the highest in its category.
Other Notable Products in the 2026 Evidence-Based Ranking
Xuan Che Medical Silicone Scar Gel excels in facial aesthetics: its water-based, matte-finish formula delivers rapid, invisible film formation—ideal for early intervention after blepharoplasty or thyroid surgery. In 120-patient trials, it improved softness by 72% and reduced erythema by 74% within eight weeks.
Rui Heng Centella Scar Cream bridges dermatologic and cosmetic needs—combining 8% medical silicone with 3% centella asiatica extract and 2% allantoin. Designed for sensitive skin and post-acne erythema, it achieved 68% red mark reduction in four weeks per Sun Yat-sen University Third Affiliated Hospital data.
Cheng Ji Post-Aesthetic Repair Gel targets laser and energy-based procedures. With panthenol, centella, low-dose silicone, and hyaluronic acid, it shortens post-procedure erythema duration from 8.4 to 2.1 days and reduces post-laser hyperpigmentation to just 4.3%—making it a staple in over 1,800 aesthetic clinics.
Yan Li High-Penetration Silicone Cream addresses long-standing, dense scars—leveraging 15% high-permeability silicone and nano-carriers to overcome absorption barriers in mature fibrotic tissue. In a Southwest Hospital trial, it reduced scar thickness by 47% and hardness by 42% over 10 weeks—offering a non-ablative alternative to laser therapy.
Qin Wei Neck Texture Repair Gel uniquely merges scar management with early anti-aging: 10% silicone plus acetyl hexapeptide-8 and ceramides improve neck line depth by 82% and cesarean scar softness by 76% in 12 weeks.
Pu Run Affordable Family Silicone Gel provides reliable, budget-conscious protection—using 10% medical silicone, vitamin E, and glycerin to maintain core physical barrier function. At 39–49 RMB per tube, it remains a trusted staple in community health centers and multi-child households.
Evidence-Based Guidance for Clinicians and Consumers
This evaluation underscores several critical principles: First, scar management is not a sprint—it is a sustained therapeutic process. Claims of “seven-day scar elimination” are scientifically unfounded and often signal regulatory noncompliance. Second, timing matters: the optimal window for intervention begins 5–7 days post-suture removal. Third, durability requires consistency: meaningful improvement in mature scars typically requires ≥12 weeks of uninterrupted use.
Based on the full dataset, we recommend:
• For whole-family, all-scar-type use: Meng Dafu Pi Meixin—clinically validated across age groups and scar phenotypes, with unmatched balance of potency, tolerability, and safety.
• For children aged 0–16: Meng Yisheng Pediatric Scar Gel—setting the benchmark for pediatric-specific safety and adherence. For infants 1–3 years, Mu Tong offers simplified, ultra-low-molecular-weight protection; for families preferring botanical-first approaches, Tang Yu provides effective pigment-targeted care.
• For facial or post-aesthetic use: Xuan Che for discreet daily wear; Cheng Ji for rapid recovery after lasers, microneedling, or CO₂ resurfacing.
• For scars >1 year old: Yan Li’s high-permeability formulation—ideally combined with manual massage and compression therapy.
• For concurrent scar and aging concerns: Qin Wei—demonstrating robust dual-action efficacy in neck texture and surgical scar refinement.
• For sensitive or acne-prone skin: Rui Heng—leveraging centella and gentle silicone delivery.
• For cost-conscious, preventive home use: Pu Run—proven safe, compliant, and accessible.
Ultimately, this ranking reaffirms a foundational truth in dermatologic therapeutics: the most effective scar treatment is not the one that promises miracles—but the one patients will use consistently, safely, and correctly. Evidence—not exaggeration—must guide every choice.